ReviewInternational journal of molecular sciences2020
Current Evidence and Future Perspectives on Pharmacological Treatment of Calcific Aortic Valve Stenosis.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Sirtuin 1 deficiency mediates chronic kidney disease-induced inflammaging cardiovascular calcification.Molecular biomedicine · 2026Article
- Gamma-Oryzanol Attenuates Aortic Valve Interstitial Cell Calcification via Suppression of BMP2-SMAD and MAPK Signaling Pathways.Biomolecules · 2026Article
- Metformin mitigates aortic valve degeneration in an ex vivo three-dimensional tissue model.Scientific reports · 2025Article
- Aortic Stenosis: Diagnosis, Molecular Mechanisms and Therapeutic Strategies-A Comprehensive Review.Journal of clinical medicine · 2025Review
- Insights into calcific aortic valve stenosis: a comprehensive overview of the disease and advancing treatment strategies.Annals of medicine and surgery (2012) · 2024Review
- The Specific Molecular Changes Induced by Diabetic Conditions in Valvular Endothelial Cells and upon Their Interactions with Monocytes Contribute to Endothelial Dysfunction.International journal of molecular sciences · 2024Article
- Quantifying the Survival Loss Linked to Late Therapeutic Indication in High-Gradient Severe Aortic Stenosis.JACC. Advances · 2024Article
- Biofunctionalized Decellularized Tissue-Engineered Heart Valve with Mesoporous Silica Nanoparticles for Controlled Release of VEGF and RunX2-siRNA against Calcification.Bioengineering (Basel, Switzerland) · 2023Article
- Pathophysiology, emerging techniques for the assessment and novel treatment of aortic stenosis.Open heart · 2023Review
- Mechanical injury accentuates lipid deposition in ApoEFrontiers in cardiovascular medicine · 2023Article
- Risk for Mortality with Increasingly Severe Aortic Stenosis: An International Cohort Study.Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography · 2023Article
- Development and validation of a new prediction model for calcific aortic valve stenosis.Journal of thoracic disease · 2022Article
- Galectin-3 promotes calcification of human aortic valve interstitial cells via the NF-kappa B signaling pathway.Cardiovascular diagnosis and therapy · 2022Article
- Bisphosphonates as Potential Inhibitors of Calcification in Bioprosthetic Heart Valves (Review).Sovremennye tekhnologii v meditsine · 2022Review
- Metformin alleviates the calcification of aortic valve interstitial cells through activating the PI3K/AKT pathway in an AMPK dependent way.Molecular medicine (Cambridge, Mass.) · 2021Article
- Article
- The Emerging Role of Nutraceuticals in Cardiovascular Calcification: Evidence from Preclinical and Clinical Studies.Nutrients · 2021Review
- Extracellular Matrix in Calcific Aortic Valve Disease: Architecture, Dynamic and Perspectives.International journal of molecular sciences · 2021Review
- Cardiologic Long-Term Follow-Up of Patients Treated With Chest Radiotherapy: When and How?Frontiers in cardiovascular medicine · 2021Article
- Elements of Immunoglobulin E Network Associate with Aortic valve Area in Patients with Acquired Aortic Stenosis.Biomedicines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Calcific aortic valve stenosis (CAVS), the most common heart valve disease, is characterized by the slow progressive fibro-calcific remodeling of the valve leaflets, leading to progressive obstruction to the blood flow. CAVS is an increasing health care burden and the development of an effective medical treatment is a major medical need. To date, no effective pharmacological therapies have proven to halt or delay its progression to the severe symptomatic stage and aortic valve replacement represents the only available option to improve clinical outcomes and to increase survival. In the present report, the current knowledge and latest advances in the medical management of patients with CAVS are summarized, placing emphasis on lipid-lowering agents, vasoactive drugs, and anti-calcific treatments. In addition, novel potential therapeutic targets recently identified and currently under investigation are reported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.